Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $3.79M rose 50.4% year over year, ahead of the -47.8% change in trailing-twelve-month other income / expenses. Sequentially, it rose 325.6% from the prior quarter. Over 3 fiscal years it compounded at -14.5% a year.
Context
- Other income / expenses amounted to 41.7% of revenue in FY2025, down 137.4 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +50.4% holds above the trailing-twelve-month pace of -47.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 5.07M USD
- Year-over-year change
- -59.6%
- 4-year CAGR
- +25.5%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.07M | -59.6% |
| FY2024 | 2024-12-31 | 12.54M | +20.1% |
| FY2023 | 2023-12-31 | 10.44M | +28.9% |
| FY2022 | 2022-12-31 | 8.1M | +297.0% |
| FY2021 | 2021-12-31 | 2.04M | — |
Other Income / Expenses vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -47.8% is the 5th highest of 11, against a peer median of -77.4%.
- Other income / expenses amounts to 37.9% of revenue for PRLD, versus a peer median of 29.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.34M USD | -47.8% | -14.5% | 37.9% | |
| LTM Mar 2026 | $5.52M USD | -41.1% | +30.8% | 39.8% | |
| LTM Mar 2026 | $5.44M USD | -67.9% | -1.8% | 19.3% | |
| LTM Mar 2026 | $4.79M USD | +95.0% | +39.6% | — | |
| LTM Mar 2026 | $2.85M USD | -27.9% | +11.8% | 1268.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $2.76M USD | +155.6% | — | — |
| LTM Mar 2026 | $325K USD | -86.9% | — | 1.0% | |
| LTM Mar 2026 | -$1.51M USD | -146.9% | +2.8% | 2.2% | |
| LTM Mar 2026 | -$2.06M USD | -113.1% | — | 18.4% | |
| LTM Mar 2026 | -$5.41M USD | -104.4% | — | 9176.3% | |
| FY2025 | -€211.38M EUR | -144.8% | — | 4715.1% | |
| Peer median (excluding PRLD) | — | -77.4% | +11.8% | 29.5% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.